

Vaccine and Disease Prevention

Wei LU DVM (BVSc), MS, PhD Director, Global Swine Biology R&D Ceva

02 MAY 2012



Who am I?

- Dr. Wei Lu
- DVM or BVSc Veterinarian China 1982
- MS University of Nebraska-Lincoln 1989
- PhD University of Nebraska Omaha Medical Center 1995
- Animal disease research (1982)
- Veterinary vaccine Research and Development (1994 -)
- ** 1st US Swine flu vaccine (H1 & H3) 2001



Post Intervention - Treatment

- Antibiotics Pharmaceutical approach
- Antiserum therapy Biological approach Rabies
 - Tetanus
- Prior Intervention Prevention
 Vaccination Biological approach





 Vaccine is a preparation containing weakened (still live) or dead microbes (part or whole) of the kind that cause a disease, administered to stimulate the immune system to produce protection against that disease





 The term vaccine derives from Edward Jenner's 1796 use of cow pox (Latin variola vaccinia, adapted from the Latin vaccīn-us, from vacca, cow), to inoculate humans, providing them protection against smallpox



1st Vaccination - Edward Jenner and Smallpox



- Edward Jenner
- Sarah Nelmes dairymaid
- James Philips (8 year old boy)
- 14 May 1796







• A vaccine is used to stimulate the body to induce specific immunity against the specific antigens (organisms)

 Immunity is a biological term that describes a state of having sufficient biological defenses to avoid infection, disease, or other unwanted biological invasion



The Types of Immunity

• Nonspecific immunity

- Includes things such as physical barriers, mucus production, inflammation, fever, and phagocytosis
- Directed against all pathogens; is the initial defense against invading agents
- Specific immunity
 - Takes over when the nonspecific mechanisms fail
 - Targeted for a specific antigen; has memory
 - Arises from B- and T-lymphocytes



The Types of Immunity

- Cell-mediated immunity
 - T-lymphocytes directly attack the invading antigen
 - Important for protecting against intracellular bacterial or viral infections, fungal diseases, and protozoal diseases
- Antibody-mediated immunity
 - B-lymphocytes produce antibodies that react to antigen
 - Important for extracellular phases of systemic viral and bacterial infections and protection against endotoxin and exotoxin-induced disease



Ways to Acquire Specific Immunity

Active immunity

- Arises when an animal receives an antigen that activates B- and T-lymphocytes
- Creates memory
- Passive immunity
 - Arises when an animal receives antibodies from another animal
 - Provides immediate onset of immunity, but the animal is protected for a shorter time (no memory)
- Natural immunity
 - Acquired during normal biological experiences
- Artificial immunity
 - Acquired through medical procedures



Vaccination

- Vaccination is the administration of antigenic material (a vaccine) to stimulate the immune system of an individual to develop adaptive immunity to a disease
- Injection intramuscular, subcutaneous and intradermal
- Oral
- Intranasal



Patient exposed to pathogen Carrying antigens A and B

It works like this





Vaccines can be divided into two types

Live attenuated

Inactivated (Killed)









Inactivated Vaccines fall into different categories

- Viruses
- Bacteria
- Individual proteins from pathogen (Subunit)
 Pathogen specific complex sugars (PLS)





Inactivated Vaccines

- No chance of recreating live pathogen
- Less interference from circulating antibody than live vaccines





Inactivated Vaccines

- Cannot replicate I the body and generally not as effective as live vaccines
- Usually require revaccination doses (boost)
- Immune response is mostly antibody based
- Safe
- Usually contain adjuvant
- Liquid form
- Contain preservatives (Thimerosal..)





Some Inactivated Vaccines

• Viral

Polio, hepatitis A, rabies, influenza

Bacterial

Pertussis, typhoid, cholera, plague







Some Inactivated Vaccines contain purified proteins rather than whole bacteria/viruses

Proteins

hepatitis B, influenza, acellular pertussis, human papillomavirus, anthrax, Lyme

 Toxins diphtheria, tetanus





- Attenuated (weakened) form of the "wild" virus or bacterium
- Can replicate themselves so the immune response is more similar to natural infection
- Usually effective with one dose





- Stimulate both cellular immunity and humoral immunity (antibody)
- Longer duration of immunity (protection) months and years
- Freeze-dried with stabilizer





Live Attenuated Vaccines - disadvantages

- Severe reactions possible especially in immune compromised patients
- Worry about recreating a wild-type pathogen that can cause disease ?
- Fragile must be stored carefully

TABLE 9. Vaccine storage temperature recommendations					
Vaccines	Vaccine storage temperature				
Diphtheria-tetanus, or pertussis-containing vaccines	35°F-46°F (2°C-8°C) Do not freeze				
Haemophilus influenzae type b conjugate vaccines (Hib)	35°F–46°F (2°C–8°C) Do not freeze				
Hepatitis A and hepatitis B vaccines	35°F–46°F (2°C–8°C) Do not freeze				
Inactivated polio vaccine	35°F-46°F (2°C-8°C) Do not freeze				
Meningococcal conjugate vaccine	35°F-46°F (2°C-8°C) Do not freeze				
Meningococcal polysaccharide vaccine	35°F-46°F (2°C-8°C) Do not freeze				

Pneumococcal conjugate vaccine	35°F-46°F (2°C-8°C) Do not freeze
Pneumococcal polysaccharide vaccine	35°F–46°F (2°C–8°C) Do not freeze
Measles, mumps, and rubella vaccine in the lyophilized (freeze-dried) state [§]	35°F-46°F (2°C-8°C) Lyophilized (freeze-dried) vaccine can be stored at freezer temperature
Measles, mumps, rubella, and varicella vaccine	<u>≤</u> 5°F (<u><</u> -15°C)
Trivalent inactivated influenza vaccine	35°F–46°F (2°C–8°C) Do not freeze
Live-attenuated influenza vaccine	≤5°F (≤-15°C)
Varicella vaccine	<u>≤</u> 5°F (<u><</u> -15°C)

Herpes zoster vaccine

5°F (≤-15°C)



Some Live Attenuated Vaccines

• Viral

- measles, mumps,
- rubella, vaccinia,
- varicella/zoster,
- yellow fever, rotavirus,
- intranasal influenza,
- oral polio
- Bacterial
 - BCG (TB), oral typhoid







Routinely Recommended Vaccines for Disease Prevention

- Diphtheria
- Haemophilus influenzae type b (Hib)
- Hepatitis A
- Hepatitis B
- Herpes zoster (shingles)
- Human papillomavirus (HPV)
- Influenza
- Measles
- Meningococcal disease

- Mumps
- Pertussis
- Pneumococcal disease
- Polio
- Rotavirus
- Rubella
- Tetanus
- Varicella (chickenpox)



Pediaric Vaccination Scedule in Europe





New Vaccine Recommendation

Rota vírus vaccine: 2, 4, 6 m HPV: 12 -26) y





Recommended Adult Immunization Schedule OCT 2005–SEPT 2006 (ACIP)

AGE (yrs)	19-49	5	0-64	>65	
Td or Tdap	1 Dose every 10 ye			ears	
Flu	1 Dose yearl	y	1 Dose yearly		
PPV23	1 Dose			1 Dose	
Hep B	3 Doses (0, 1, 6 mos)				
Нер А	2 Doses (0, 6-12 mos)				
MMR	1 or 2 Doses				
VZV	2 Doses				
MCV4/MPSV4	1 Dose				
Everyone	If at 1	risk	No	disease/No record	





- Affects mostly children under 3 (50% of all cases)
- Asymptomatic, 10% with 'minor illness': fever, nausea, vomiting
- 0.5 -1% infections leads to irreversible paralysis (AFP), with maximum effect taking place in 3-4 days
- Legs affected more than arms; paralysis of respiratory muscles is life-threatening
- Humans are the only reservoir for the poliovirus. The virus does not naturally reproduce in any other species.

















Evidence of sporadic epidemics of polio predate recorded history

- **1789**, British physician Michael Underwood first clinical description of the disease.
- **1840**, Jacob Heine clinical features of the disease and its involvement of the spinal cord.
- 1894, first outbreak of polio in epidemic form in the U.S. occurs





- **1908**, Karl Landsteiner & Erwin Popper identify the polio virus by transmitting the disease to a monkey.
- 1916, large epidemic of polio in the US
- 1921, FDR contracts polio (at 39).
- **1929**, Philip Drinker & Louis Shaw develop the "iron lung" to aid respiration.



- **1930s**, 2 strains of the poliovirus are discovered (later it was determined that there were 3).
- 1933, FDR inaugurated president.
- 1935, Maurice Brodie & John Kolmer test polio vaccines, with disastrous results.
- **1947 50**, Dr. Jonas Salk is recruited by the University of Pittsburgh to develop a virus research program.
- **1953**, Salk and associates develop a potentially safe, inactivated (killed), injected polio vaccine.



- 1954, ~2 m children participate in the field trials.
- **1955**, news of the success of the trials is announced by Dr. Thomas Francis on April 12, the tenth anniversary of FDR's death.
- 1955 57, incidence of polio in the U.S. falls by 85 - 90%.
- **1957 59**, mass clinical trials of Albert Sabin's live, attenuated vaccine in Russia.
- **1962**, the Salk vaccine replaced by the Sabin vaccine for most purposes because it is easier to administer and less expensive.



- **1979**, last case of polio caused by "wild" virus in U.S.; last case of smallpox in the world.
- **1980**, the first National Immunization Day for polio held in Brazil.
- 1988, Rotary International, PanAmerican HO, WHO, CDC, UNICEF begin international campaign to stop transmission of polio everywhere in the world.
- **1999**, inactivated polio vaccine replaces oral polio vaccince as recommended method of polio immunization in the United States.



Salk Polio Vaccine

Formaldehyde-fixed No reversion





Sabin Polio Vaccine

- Attenuated by passage in foreign host (monkey kidney cells)
- Selection to grow in new host
- less suited to original host
- Grows in epithelial cells
- Does not grow in nerves
- No paralysis
- Local gut immunity (IgA)







Vaccination: Salk vs Sabin

- IPV (Salk): Also induces humoral immunity via antibodies. However, it induces very low levels of immunity to poliovirus locally, inside the gut. As a result, it provides individual protection against polio paralysis but, unlike OPV, cannot prevent the spread of wild polio virus.
- OPV (Sabin): provides immunity to all 3 strains of polio. Induces humoral immunity systemically as well as local GI mucosal immunity (which limits transmission during outbreaks).

Ceva

Live virus generates a more complete immune response





Polio Case in the US





Global number of poliomyelitis cases, 1980-2004





















Regulation of Vaccines

Human vaccines Food and Drug Administration

Veterinary Vaccines USDA Center for Veterinary Biological



Requirements for Vaccine Manufacturers

- Permit for each manufacturer
- Product license for each vaccine
- Strict guidelines in development, production, quality control testing procedures to ensure:
 - **Safe** ensure the safety in all ages and conditions
 - Pure ensure the purity of seeds, raw materials and final product
 - **Potent** potency test for each serial before releasing
 - Efficacious complete demonstration of efficacy (protection) before license



New Vaccine Development

- Veterinary Vaccines (avg. 3-6 + year)
 - Research
 - Development
 - Clinical

• Human Vaccines (avg. 5-10 + years)

- Phase 1
- Phase 2
- Phase 3
- Phase 4



- Vaccination vs non-vaccination ?
- Does a vaccine work for everyone? 100% safe?
- Religion and politics







 Vaccines help the prevention of infectious diseases and save lives in humans and animals!



Thank you for your attention!